Cancer Pretest Decisions and Counseling (CME)

Cancer Pretest Decisions and Counseling (CME)

Practice deciding when and if genetic testing is appropriate, given a patient's clinical and personal context.

rate limit

Code not recognized.

About this course

Communicating with patients about benefits and limitations of genetic testing is an important part of informed decision-making. In this course, you will watch a short video of a patient and provider discussion about patient motivations for genetic testing. You will practice deciding when and if genetic testing is appropriate, given the clinical and personal context, and be presented with tools to help make this task easy to implement in your practice.

To claim credit, follow the steps in the learning path.


CME Information and Disclosures

Jointly Provided by The Jackson Laboratory and the University of Connecticut School of Medicine Office of Community and Continuing Medical Education

Original Release: February 24, 2015
Renewal Date: July 1, 2023
Expiration Date: June 30, 2026

Learning Objectives

  • Communicate the benefits and limitations of genetic testing to patients.

Target Audience
Practicing primary care providers as well as students and residents.

Accreditation

The University of Connecticut School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Connecticut School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming Your Credit
In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 2 out of 4 questions correctly and 4) complete the evaluation.   
 

Conflict of Interest Policy
All faculty members participating in CME activities sponsored by the University of Connecticut School of Medicine are required to disclose to the program audience any actual or apparent conflict of interest related to the content of their presentations. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. 

Planners, Writers, and Reviewers
  • Emily Edelman, MS, CGC – The Jackson Laboratory 
  • Therese Ingram, MA – The Jackson Laboratory 
  • Kalisi Logan, MS, CGC – The Jackson Laboratory 
  • Kate Reed, MPH, ScM, CGC – The Jackson Laboratory 
  • Linda Steinmark, MS, CGC – The Jackson Laboratory 
  • Hayley Dunnack Yackel, PhD, RN, CMSRN, OCN – Hartford Healthcare Cancer Institute 
  • Fatima Amir, MS, CGC - Genome Medical

Disclosure Statement

The activity director, the co-activity director, planning committee, writers and reviewers for this educational event have no relevant financial relationship(s) with any ineligible companies that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation that needs to be disclosed. This educational event will not be discussing the off-labeled or investigational use of any product or device.

Actors are being used in this program and are presenting information that has been scripted for them. They were not involved with the educational content of this activity. 

Commercial Support

This CME activity has no commercial support associated with it.

References

Berliner JL, Cummings SA, Boldt Burnett B, Ricker CN. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2021; 30(2):342-360. 

Esteban I, Lopez-Fernandez A, Balmaña J. A Narrative Overview of the Patients’ Outcomes after Multigene Cancer Panel Testing, and a Thorough Evaluation of its Implications for Genetic Counselling.European Journal of Medical Genetics. 2019; 62(5):342-349. 

Holter S, Hall MJ, Hampel H, et al. Risk assessment and genetic counseling for Lynch syndrome - Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. J Genet Couns. 2022;31(3):568-583.  

Lumish HS, Steinfeld H, Koval C, et al. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.J Genet Counsel. 2017; 26(5):1116-1129. 

National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Detection, Prevention and Risk Reduction. (Requires free registration). 

Owens DK, Davidson KW, Krist AH, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. JAMA. 2019; 322(7):652-. 

Price KS, Svenson A, King E, Ready K, Lazarin GA. Inherited Cancer in the Age of Next-Generation Sequencing.Biological Research For Nursing. 2018; 20(2):192-204. 

Russo J, Giri VN. Germline testing and genetic counselling in prostate cancer. Nat Rev Urol. 2022;19(6):331-343. 


Hardware/Software Requirements

Audio speakers or headphones

Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher

Check the supported browsers.

Should you have technical questions or questions regarding the content of the activity, please email Clinical Education at the Jackson Laboratory.


Disclaimer

All information in Cancer Genetic Clinical Education is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Cancer Genetic Clinical Education. Reliance on any information in Cancer Genetic Clinical Education is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Cancer Genetic Clinical Education.

Learning Path

  • Pre-assessment
  • Pre-course assessment

    The pre-test is required to access the educational material.

  • Review Course Materials
  • Cancer Pretest Decisions & Counseling

    Contains the educational material.

  • Post Quiz & Evaluation
  • Post-course assessment

    Passing the post-test is required to earn a certificate.

  • Evaluation
  • Accessing your certificate
  • Resources

    The resources and references are the same as found in the course material. 

  • Tools & resources

    Additional resources for more learning about genomic tumor testing

  • More education
  • References

    References used to develop the content

About this course

Communicating with patients about benefits and limitations of genetic testing is an important part of informed decision-making. In this course, you will watch a short video of a patient and provider discussion about patient motivations for genetic testing. You will practice deciding when and if genetic testing is appropriate, given the clinical and personal context, and be presented with tools to help make this task easy to implement in your practice.

To claim credit, follow the steps in the learning path.


CME Information and Disclosures

Jointly Provided by The Jackson Laboratory and the University of Connecticut School of Medicine Office of Community and Continuing Medical Education

Original Release: February 24, 2015
Renewal Date: July 1, 2023
Expiration Date: June 30, 2026

Learning Objectives

  • Communicate the benefits and limitations of genetic testing to patients.

Target Audience
Practicing primary care providers as well as students and residents.

Accreditation

The University of Connecticut School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Connecticut School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming Your Credit
In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 2 out of 4 questions correctly and 4) complete the evaluation.   
 

Conflict of Interest Policy
All faculty members participating in CME activities sponsored by the University of Connecticut School of Medicine are required to disclose to the program audience any actual or apparent conflict of interest related to the content of their presentations. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. 

Planners, Writers, and Reviewers
  • Emily Edelman, MS, CGC – The Jackson Laboratory 
  • Therese Ingram, MA – The Jackson Laboratory 
  • Kalisi Logan, MS, CGC – The Jackson Laboratory 
  • Kate Reed, MPH, ScM, CGC – The Jackson Laboratory 
  • Linda Steinmark, MS, CGC – The Jackson Laboratory 
  • Hayley Dunnack Yackel, PhD, RN, CMSRN, OCN – Hartford Healthcare Cancer Institute 
  • Fatima Amir, MS, CGC - Genome Medical

Disclosure Statement

The activity director, the co-activity director, planning committee, writers and reviewers for this educational event have no relevant financial relationship(s) with any ineligible companies that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation that needs to be disclosed. This educational event will not be discussing the off-labeled or investigational use of any product or device.

Actors are being used in this program and are presenting information that has been scripted for them. They were not involved with the educational content of this activity. 

Commercial Support

This CME activity has no commercial support associated with it.

References

Berliner JL, Cummings SA, Boldt Burnett B, Ricker CN. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes—Practice resource of the National Society of Genetic Counselors. J Genet Couns. 2021; 30(2):342-360. 

Esteban I, Lopez-Fernandez A, Balmaña J. A Narrative Overview of the Patients’ Outcomes after Multigene Cancer Panel Testing, and a Thorough Evaluation of its Implications for Genetic Counselling.European Journal of Medical Genetics. 2019; 62(5):342-349. 

Holter S, Hall MJ, Hampel H, et al. Risk assessment and genetic counseling for Lynch syndrome - Practice resource of the National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer. J Genet Couns. 2022;31(3):568-583.  

Lumish HS, Steinfeld H, Koval C, et al. Impact of Panel Gene Testing for Hereditary Breast and Ovarian Cancer on Patients.J Genet Counsel. 2017; 26(5):1116-1129. 

National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Detection, Prevention and Risk Reduction. (Requires free registration). 

Owens DK, Davidson KW, Krist AH, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. JAMA. 2019; 322(7):652-. 

Price KS, Svenson A, King E, Ready K, Lazarin GA. Inherited Cancer in the Age of Next-Generation Sequencing.Biological Research For Nursing. 2018; 20(2):192-204. 

Russo J, Giri VN. Germline testing and genetic counselling in prostate cancer. Nat Rev Urol. 2022;19(6):331-343. 


Hardware/Software Requirements

Audio speakers or headphones

Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher

Check the supported browsers.

Should you have technical questions or questions regarding the content of the activity, please email Clinical Education at the Jackson Laboratory.


Disclaimer

All information in Cancer Genetic Clinical Education is provided for educational purposes only. This information is not a substitute for clinical guidance or the consultation of a medical professional. Always seek the advice of a qualified health professional with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in Cancer Genetic Clinical Education. Reliance on any information in Cancer Genetic Clinical Education is solely at your own risk. The Jackson Laboratory does not endorse or recommend any specific procedures, tests, products, services, health professionals or other information that may be found in Cancer Genetic Clinical Education.

Learning Path

  • Pre-assessment
  • Pre-course assessment

    The pre-test is required to access the educational material.

  • Review Course Materials
  • Cancer Pretest Decisions & Counseling

    Contains the educational material.

  • Post Quiz & Evaluation
  • Post-course assessment

    Passing the post-test is required to earn a certificate.

  • Evaluation
  • Accessing your certificate
  • Resources

    The resources and references are the same as found in the course material. 

  • Tools & resources

    Additional resources for more learning about genomic tumor testing

  • More education
  • References

    References used to develop the content